Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2014-06-24
Original SEC Filing: Click here

---

Webplus: SVA/20140624/6-K/2_EX-99.1/000.htm SEC Original: v382173_ex99-1.htm
Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) — Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating

---

---

Webplus: SVA/20140624/6-K/3_EX-99.2/000.htm SEC Original: v382173_ex99-2.htm
Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company

---

---

Webplus: SVA/20140624/6-K/4_EX-99.3/000.htm SEC Original: v382173_ex99-3.htm
Sinovac Reports Unaudited First Quarter 2014 Financial Results — -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results – Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT – BEIJING, May 21, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products

---

---

Webplus: SVA/20140624/6-K/1/000.htm SEC Original: v382173_6k.htm

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2014-06-24CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085